Form 4: Castle Biosciences Director Exercises Stock Options
SEC Form 4 Filing
Director Kim Caple exercised stock options on July 14, 2024, acquiring 440 shares of Castle Biosciences common stock.
Summary
- On July 14, 2024, Kim Caple, a director of Castle Biosciences, exercised stock options.
- This transaction resulted in the acquisition of 440 shares of common stock.
- Following the transaction, Caple directly owns 13,781 shares of Castle Biosciences common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard disclosure of stock option exercise.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This provides transparency to the market regarding insider activity.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it involves a small number of shares relative to the company's total outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 07/14/2021 | Reporting Person was granted 1,320 RSUs which vest in three equal annual installments beginning on July 14, 2022. |
| 07/14/2022 | First vesting date of Restricted Stock Units (RSUs) granted on July 14, 2021. |
| 07/14/2024 | Date of transaction: Director Kim Caple exercised stock options, acquiring 440 shares of common stock. |
| 07/16/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.